董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas P. Mathers | 男 | Chief Executive Officer and Director | 49 | 665.77万美元 | 未持股 | 2016-03-24 |
| Martin Edwards | 男 | Director | 60 | 未披露 | 未持股 | 2016-03-24 |
| Luc Marengere | 男 | Director | 50 | 6.57万美元 | 未持股 | 2016-03-24 |
| Mark Corrigan | 男 | Director | 58 | 2.93万美元 | 未持股 | 2016-03-24 |
| Marvin L. White | 男 | Director | 54 | 6.24万美元 | 未持股 | 2016-03-24 |
| Arthur M. Pappas | 男 | Chairman of the Board | 68 | 未披露 | 未持股 | 2016-03-24 |
| Alison Lawton | 女 | Director | 54 | 未披露 | 未持股 | 2016-03-24 |
| Arthur M. Pappas | 男 | Chairman of the Board | 68 | 8.96万美元 | 未持股 | 2016-03-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas P. Mathers | 男 | Chief Executive Officer and Director | 49 | 665.77万美元 | 未持股 | 2016-03-24 |
| Matthew D. Dallas | 男 | Chief Financial Officer | 40 | 170.98万美元 | 未持股 | 2016-03-24 |
| Bernice Kuca | 女 | Head, Clinical and Regulatory Operations | 57 | 218.65万美元 | 未持股 | 2016-03-24 |
| Linda C. Hogan | 女 | Head, Business Development and Strategy | 64 | 12.00万美元 | 未持股 | 2016-03-24 |
| Raymond D. Skwierczynski | 男 | Head, Pharmaceuticals Operations | 53 | 未披露 | 未持股 | 2016-03-24 |
董事简历
中英对照 | 中文 | 英文- Thomas P. Mathers
-
Thomas P. Mathers自2011年6月以来一直担任我们的首席执行官。2015年1月以来，他一直担任我们董事会的成员。2011年6月以来，他担任Déclion Holdings LLC（生物技术公司，从事declensional peptides的开发，神经退行性疾病，传染性疾病和癌症的治疗平台）和其附属公司的主席和首席执行官。2006年6月以来，他一直任职生物技术工业组织的董事会职务。直到2014年12月，他担任CureFAKtor Pharmaceuticals, LLC（一个私营生物制药公司）的临时总经理。此前从2003年11月到2011年6月Peptimmune, Inc.根据破产法第7章（Chapter 7 bankruptcy）申请破产，他担任Peptimmune, Inc.（生物科技公司，从事肽和氨基酸共聚物的开发，来治疗中枢神经系统和慢性炎性疾病）的总裁、首席执行官和董事。此前，他曾是Cell Based Delivery, Inc.的总裁、首席执行官和董事。他曾是Cardion Pharmaceuticals, Inc. 的总经理和公司副总裁。他曾在Genzyme Corporation担任各种职务，包括战略发展副总裁、心血管全球营销高级董事以及各种营销管理职位。他曾担任 CureFAKtor Pharmaceuticals, LLC公司的董事（从2012年5月到2014年12月）。从1988年到1991年，他担任美国陆军航空（the United States Army - Aviation）的上尉。1988年他获得西点军校（West Point）美国军事学院（United States Military Academy）的工程学士学位。
Thomas P. Mathers has served as our Chief Executive Officer since June 2011. Since January 2015 Mr. Mathers has also served as a member of our Board of Directors. He also serves as the Chairman and Chief Executive Officer of Déclion Holdings LLC, a biotechnology company focused on developing declensional peptides as a platform for the treatment of neurodegenerative diseases, infectious diseases and cancer, and its affiliates and has held these roles since June 2011. Since June 2006 Mr. Mathers has served on the board of directors of the Biotechnology Industry Organization. Until December 2014 Mr. Mathers also served as the interim general manager of CureFAKtor Pharmaceuticals, LLC, a privately held biopharmaceutical company. Previously, Mr. Mathers served as the President and Chief Executive Officer and a director of Peptimmune, Inc., a biotechnology company focused on developing peptides and amino acid copolymers for the treatment of CNS and chronic inflammatory diseases, from November 2003 until June 2011 when the company filed for Chapter 7 bankruptcy. Prior to that, Mr. Mathers was the President and Chief Executive Officer and a director of Cell Based Delivery, Inc., and he was the General Manager and Corporate Vice President of Cardion Pharmaceuticals, Inc. Mr. Mathers also held a variety of positions at Genzyme Corporation, including Vice President, Strategic Development; Senior Director, Cardiovascular Global Marketing; and various marketing management positions. He also served as a director of CureFAKtor Pharmaceuticals, LLC from May 2012 to December 2014. Mr. Mathers served as a captain in the United States Army-Aviation from 1988 through 1991 and he received his bachelor’s degree in engineering from the United States Military Academy, West Point, in 1988. - Thomas P. Mathers自2011年6月以来一直担任我们的首席执行官。2015年1月以来，他一直担任我们董事会的成员。2011年6月以来，他担任Déclion Holdings LLC（生物技术公司，从事declensional peptides的开发，神经退行性疾病，传染性疾病和癌症的治疗平台）和其附属公司的主席和首席执行官。2006年6月以来，他一直任职生物技术工业组织的董事会职务。直到2014年12月，他担任CureFAKtor Pharmaceuticals, LLC（一个私营生物制药公司）的临时总经理。此前从2003年11月到2011年6月Peptimmune, Inc.根据破产法第7章（Chapter 7 bankruptcy）申请破产，他担任Peptimmune, Inc.（生物科技公司，从事肽和氨基酸共聚物的开发，来治疗中枢神经系统和慢性炎性疾病）的总裁、首席执行官和董事。此前，他曾是Cell Based Delivery, Inc.的总裁、首席执行官和董事。他曾是Cardion Pharmaceuticals, Inc. 的总经理和公司副总裁。他曾在Genzyme Corporation担任各种职务，包括战略发展副总裁、心血管全球营销高级董事以及各种营销管理职位。他曾担任 CureFAKtor Pharmaceuticals, LLC公司的董事（从2012年5月到2014年12月）。从1988年到1991年，他担任美国陆军航空（the United States Army - Aviation）的上尉。1988年他获得西点军校（West Point）美国军事学院（United States Military Academy）的工程学士学位。
- Thomas P. Mathers has served as our Chief Executive Officer since June 2011. Since January 2015 Mr. Mathers has also served as a member of our Board of Directors. He also serves as the Chairman and Chief Executive Officer of Déclion Holdings LLC, a biotechnology company focused on developing declensional peptides as a platform for the treatment of neurodegenerative diseases, infectious diseases and cancer, and its affiliates and has held these roles since June 2011. Since June 2006 Mr. Mathers has served on the board of directors of the Biotechnology Industry Organization. Until December 2014 Mr. Mathers also served as the interim general manager of CureFAKtor Pharmaceuticals, LLC, a privately held biopharmaceutical company. Previously, Mr. Mathers served as the President and Chief Executive Officer and a director of Peptimmune, Inc., a biotechnology company focused on developing peptides and amino acid copolymers for the treatment of CNS and chronic inflammatory diseases, from November 2003 until June 2011 when the company filed for Chapter 7 bankruptcy. Prior to that, Mr. Mathers was the President and Chief Executive Officer and a director of Cell Based Delivery, Inc., and he was the General Manager and Corporate Vice President of Cardion Pharmaceuticals, Inc. Mr. Mathers also held a variety of positions at Genzyme Corporation, including Vice President, Strategic Development; Senior Director, Cardiovascular Global Marketing; and various marketing management positions. He also served as a director of CureFAKtor Pharmaceuticals, LLC from May 2012 to December 2014. Mr. Mathers served as a captain in the United States Army-Aviation from 1988 through 1991 and he received his bachelor’s degree in engineering from the United States Military Academy, West Point, in 1988.
- Martin Edwards
-
Martin Edwards自2015年1月起担任公司董事Dr. Edwards曾担任Novo A/S（丹麦一家有限责任公司，管理投资和金融资产）资深合伙人，他担任该职位一直到2003年10月。他是Vantia Ltd.、NeRRe Therapeutics Ltd.和Epsilon 3 Bio Ltd.董事长，这些公司都是临床分期制药公司。他还担任Tarsa Therapeutics Inc.（一家制药开发公司）、KalVista Ltd.、Karus Therapeutics Ltd.以及Acacia Pharma Ltd.董事，这些公司都是位于英国的制药公司。担任现任职位之前，Dr. Edwards从1998年到2003年担任ReNeuron Ltd.（一家总部位于英国的干细胞研究公司）首席执行官；2001年带领公司上市。他在应该曼彻斯特接受生理学与医学训练；在Warwick University接受业务训练。
Martin Edwards has served as a member of our Board since June 2019. He currently also serves on the board of directors of Verona Pharma, Reata Pharmaceuticals, Inozyme Pharma Inc. and Morphic Therapeutic. Dr. Edwards recently retired as a Senior Partner at Novo Ventures, the venture capital arm of Novo A/S from 2003 to 2020. Earlier in his career, he was Corporate VP and Global Head of Drug Development for Novo Nordisk A/S, where he led pre-clinical and clinical drug development. Previously, Dr. Edwards was Chief Executive Officer of ReNeuron Ltd. and Chief Medical Officer/Vice President at Zymogenetics. Dr. Edwards was trained in physiology and medicine at the University of Manchester, where he obtained his MBChB. He was elected a Member of the Royal College of Physicians, a Member with distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine and holds an MBA from the University of Warwick. In 2009 Dr. Edwards was made Adjunct Professor at CBS SIMI in Copenhagen. - Martin Edwards自2015年1月起担任公司董事Dr. Edwards曾担任Novo A/S（丹麦一家有限责任公司，管理投资和金融资产）资深合伙人，他担任该职位一直到2003年10月。他是Vantia Ltd.、NeRRe Therapeutics Ltd.和Epsilon 3 Bio Ltd.董事长，这些公司都是临床分期制药公司。他还担任Tarsa Therapeutics Inc.（一家制药开发公司）、KalVista Ltd.、Karus Therapeutics Ltd.以及Acacia Pharma Ltd.董事，这些公司都是位于英国的制药公司。担任现任职位之前，Dr. Edwards从1998年到2003年担任ReNeuron Ltd.（一家总部位于英国的干细胞研究公司）首席执行官；2001年带领公司上市。他在应该曼彻斯特接受生理学与医学训练；在Warwick University接受业务训练。
- Martin Edwards has served as a member of our Board since June 2019. He currently also serves on the board of directors of Verona Pharma, Reata Pharmaceuticals, Inozyme Pharma Inc. and Morphic Therapeutic. Dr. Edwards recently retired as a Senior Partner at Novo Ventures, the venture capital arm of Novo A/S from 2003 to 2020. Earlier in his career, he was Corporate VP and Global Head of Drug Development for Novo Nordisk A/S, where he led pre-clinical and clinical drug development. Previously, Dr. Edwards was Chief Executive Officer of ReNeuron Ltd. and Chief Medical Officer/Vice President at Zymogenetics. Dr. Edwards was trained in physiology and medicine at the University of Manchester, where he obtained his MBChB. He was elected a Member of the Royal College of Physicians, a Member with distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine and holds an MBA from the University of Warwick. In 2009 Dr. Edwards was made Adjunct Professor at CBS SIMI in Copenhagen.
- Luc Marengere
-
Luc Marengere自2015年1月起担任公司董事。自2012年3月起Dr. Marengere开始担任蒙特利尔TVM Life Science Management Inc.管理合伙人。加入TVM Life Science之前，他从2001年10月到2012年3月担任VG Partners管理合伙人，成功发布并监管VG Advanced Life Sciences 基金的运营和投资。开启风险投资职业生涯之前，他在Amgen, Inc.（ NASDAQ：AMGN，一家生物技术公司）的肿瘤学和免疫学领域完成商业化研究。现在，Dr. Marengere担任Ixchelsis, Ltd.（一家以英国为基地的独立生物技术公司）以及PRCL Research Inc.（一家位于加拿大的制药公司）董事。他之前曾在多家私人控股公司担任董事。他持有the University of Toronto博士学位，专业是医学遗传学和分子生物物理学。
Luc Marengere has served as a member of our Board of Directors since January 2015. Dr. Marengere is Managing Partner of TVM Life Science Venture VII, which he joined in March 2012. He oversees the establishment of the new Canadian operations and the North American investment strategy as well as the deal sourcing and execution. Dr. Marengere is also responsible for ongoing relationships with certain Canadian limited partnerships and Korean investors. Dr. Marengere has 20 years of venture capital experience in Canada and the United States. Prior to joining TVM Capital, he was a Managing General Partner with VG Partners from October 2001 to March 2012 where he successfully launched and oversaw the operations and investments of the VG Advanced Life Sciences Fund. Dr. Marengere also founded the life science practice and team within VG Partners and raised more than $230 million for the first fully dedicated life science fund, VG Advanced Life Science Fund. Dr. Marengere is also currently a director of Ixchelsis, Ltd., an independent biotechnology company based in the United Kingdom, PRCL Research Inc., a pharmaceutical company based in Canada, and Modulate Therapeutics, Inc., based in Canada. He has previously served on a number of boards for publicly and privately held companies. Prior to his venture capital career, Dr. Marengere conducted commercially oriented research in the fields of immunology and oncology while at Amgen, Inc., a biotechnology company. He holds a Ph.D. from the University of Toronto's department of Medical Biophysics and Molecular Genetics and a master's degree of Science from Queen's University, and he graduated magna cum laude from the University of Ottawa. - Luc Marengere自2015年1月起担任公司董事。自2012年3月起Dr. Marengere开始担任蒙特利尔TVM Life Science Management Inc.管理合伙人。加入TVM Life Science之前，他从2001年10月到2012年3月担任VG Partners管理合伙人，成功发布并监管VG Advanced Life Sciences 基金的运营和投资。开启风险投资职业生涯之前，他在Amgen, Inc.（ NASDAQ：AMGN，一家生物技术公司）的肿瘤学和免疫学领域完成商业化研究。现在，Dr. Marengere担任Ixchelsis, Ltd.（一家以英国为基地的独立生物技术公司）以及PRCL Research Inc.（一家位于加拿大的制药公司）董事。他之前曾在多家私人控股公司担任董事。他持有the University of Toronto博士学位，专业是医学遗传学和分子生物物理学。
- Luc Marengere has served as a member of our Board of Directors since January 2015. Dr. Marengere is Managing Partner of TVM Life Science Venture VII, which he joined in March 2012. He oversees the establishment of the new Canadian operations and the North American investment strategy as well as the deal sourcing and execution. Dr. Marengere is also responsible for ongoing relationships with certain Canadian limited partnerships and Korean investors. Dr. Marengere has 20 years of venture capital experience in Canada and the United States. Prior to joining TVM Capital, he was a Managing General Partner with VG Partners from October 2001 to March 2012 where he successfully launched and oversaw the operations and investments of the VG Advanced Life Sciences Fund. Dr. Marengere also founded the life science practice and team within VG Partners and raised more than $230 million for the first fully dedicated life science fund, VG Advanced Life Science Fund. Dr. Marengere is also currently a director of Ixchelsis, Ltd., an independent biotechnology company based in the United Kingdom, PRCL Research Inc., a pharmaceutical company based in Canada, and Modulate Therapeutics, Inc., based in Canada. He has previously served on a number of boards for publicly and privately held companies. Prior to his venture capital career, Dr. Marengere conducted commercially oriented research in the fields of immunology and oncology while at Amgen, Inc., a biotechnology company. He holds a Ph.D. from the University of Toronto's department of Medical Biophysics and Molecular Genetics and a master's degree of Science from Queen's University, and he graduated magna cum laude from the University of Ottawa.
- Mark Corrigan
-
Mark Corrigan, M.D.，2015年10月以来，他担任我们董事会成员。他目前担任EPIRUS Biopharmaceuticals, Inc.的董事。他也曾担任其董事（2009年12月以来）和董事长（2014年以来）。2015年以了，他也在 Cardiome Pharma Corp.（上市公司心血管治疗）的董事会任职并在薪酬委员会任职。从2010年1月到2014年7月，Zalicus, Inc.和EPIRUS Biopharmaceuticals两家公司合并，他担任Zalicus, Inc.（ EPIRUS Biopharmaceuticals的前身）的总裁个首席执行官。从2003年4月到2009年12月，他曾是Sunovion Pharmaceuticals Inc.（原Sepracor Inc.）的研发执行副总裁。加入Sunovion Pharmaceuticals之前，他在Pharmacia & Upjohn, Inc.任职10年，最后担任部门副总裁，负责全球临床研究和实验医学。加入制药业之前，他在University of North Carolina Medical School进行学术研究5年，主要从事精神神经内分泌学。从2008年到2015年，他在Cubist Pharmaceuticals, Inc. （被Merck & Co., Inc.收购，上市的生物制药公司），他曾其审计委员会任职。从2014年到2015年，他担任Avanir Pharmaceuticals （被Otsuka Pharmaceutical Company, Ltd.收购，上市公司）的董事会职务，他担任其科学委员会的主席并子啊提名和公司治理委员会任职。
Mark Corrigan has served on our board of directors since June 23 2017. Dr. Corrigan previously served on the supervisory board of Nabriva Austria from October 2016 until the Redomiciliation. Dr. Corrigan has been the chief executive officer of Correvio Pharma Corporation formerly Cardiome Pharma, a public biopharmaceutical company, since March 2019. From April 2016 until March 2019 Dr. Corrigan was president of research and development of Tremeau Pharmaceuticals Inc. Dr. Corrigan served as president and chief executive officer of Zalicus, Inc. from January 2010 until July 2014. Previously, Dr. Corrigan was executive vice president of research and development at the specialty pharmaceutical company Sepracor Inc., and prior to this, he spent 10 years with Pharmacia & Upjohn, most recently as group vice president of Global Clinical Research and Experimental Medicine. Dr. Corrigan currently serves on the boards of directors of Correvio Pharma Corporation, Wave Life Science, a public biotechnology company, and Tremeau Pharmaceuticals, a private company. He previously served as chairman of the boards of directors of Novelion Therapeutics, Inc., BlackThorn Therapeutics, Inc., and EPIRUS Biopharmaceuticals, Inc. and as a director of CoLucid Pharmaceuticals, Inc., Cubist Pharmaceuticals, Inc., and Avanair Pharmaceuticals, Inc. Dr. Corrigan holds an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. - Mark Corrigan, M.D.，2015年10月以来，他担任我们董事会成员。他目前担任EPIRUS Biopharmaceuticals, Inc.的董事。他也曾担任其董事（2009年12月以来）和董事长（2014年以来）。2015年以了，他也在 Cardiome Pharma Corp.（上市公司心血管治疗）的董事会任职并在薪酬委员会任职。从2010年1月到2014年7月，Zalicus, Inc.和EPIRUS Biopharmaceuticals两家公司合并，他担任Zalicus, Inc.（ EPIRUS Biopharmaceuticals的前身）的总裁个首席执行官。从2003年4月到2009年12月，他曾是Sunovion Pharmaceuticals Inc.（原Sepracor Inc.）的研发执行副总裁。加入Sunovion Pharmaceuticals之前，他在Pharmacia & Upjohn, Inc.任职10年，最后担任部门副总裁，负责全球临床研究和实验医学。加入制药业之前，他在University of North Carolina Medical School进行学术研究5年，主要从事精神神经内分泌学。从2008年到2015年，他在Cubist Pharmaceuticals, Inc. （被Merck & Co., Inc.收购，上市的生物制药公司），他曾其审计委员会任职。从2014年到2015年，他担任Avanir Pharmaceuticals （被Otsuka Pharmaceutical Company, Ltd.收购，上市公司）的董事会职务，他担任其科学委员会的主席并子啊提名和公司治理委员会任职。
- Mark Corrigan has served on our board of directors since June 23 2017. Dr. Corrigan previously served on the supervisory board of Nabriva Austria from October 2016 until the Redomiciliation. Dr. Corrigan has been the chief executive officer of Correvio Pharma Corporation formerly Cardiome Pharma, a public biopharmaceutical company, since March 2019. From April 2016 until March 2019 Dr. Corrigan was president of research and development of Tremeau Pharmaceuticals Inc. Dr. Corrigan served as president and chief executive officer of Zalicus, Inc. from January 2010 until July 2014. Previously, Dr. Corrigan was executive vice president of research and development at the specialty pharmaceutical company Sepracor Inc., and prior to this, he spent 10 years with Pharmacia & Upjohn, most recently as group vice president of Global Clinical Research and Experimental Medicine. Dr. Corrigan currently serves on the boards of directors of Correvio Pharma Corporation, Wave Life Science, a public biotechnology company, and Tremeau Pharmaceuticals, a private company. He previously served as chairman of the boards of directors of Novelion Therapeutics, Inc., BlackThorn Therapeutics, Inc., and EPIRUS Biopharmaceuticals, Inc. and as a director of CoLucid Pharmaceuticals, Inc., Cubist Pharmaceuticals, Inc., and Avanair Pharmaceuticals, Inc. Dr. Corrigan holds an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.
- Marvin L. White
-
Marvin L. White，目前担任董事的任期始于2020年10月。White先生曾担任Aptevo Therapeutics Inc.（“Aptevo”）的总裁兼首席执行官，并自2016年8月起担任其董事会成员。White先生于2010年6月首次担任Emergent的董事，直到2016年5月从Emergent董事会辞职。在加入Aptevo之前，他还曾担任Emergent的顾问。从2008年到2014年3月，White先生担任St. Vincent Health的首席财务官，负责所有19家医院和36家合资企业的财务、材料管理、会计、患者财务服务和管理式医疗。在2008年加入St. Vincent Health之前，White先生是Lilly USA（礼来公司的子公司）的首席财务官，他还曾在该公司的企业战略集团担任财务和企业融资以及投资银行方面的领导职务。怀特先生是OneAmerica Financial Insurance Partners，Inc.的董事，该公司是一家位于印第安纳州印第安纳波利斯的相互保险和金融服务公司，也是一家位于西雅图的牙科保险公司Delta Dental of Washington。从2014年6月到2016年8月，White先生在Washington Prime Group的董事会任职，这是一家投资于购物中心的NYSE REIT。从2015年7月到2017年3月，怀特先生在上市制药公司CoLucid Pharmaceuticals，Inc.的董事会任职。White先生获得了威尔伯福斯大学会计学学士学位和印第安纳大学金融硕士学位。
Marvin L. White,current tenure as a director began in October 2020. Mr. White has served as President and Chief Executive Officer of Aptevo Therapeutics Inc. ("Aptevo") and as a member of its Board of Directors since August 2016. Mr. White first served as a director of Emergent in June 2010, until his resignation from the Emergent Board of Directors in May 2016. He also served as a consultant to Emergent prior to joining Aptevo. From 2008 to March 2014, Mr. White served as the Chief Financial Officer of St. Vincent Health, and was responsible for finance, materials management, accounting, patient financial services and managed care for all 19 hospitals and 36 joint ventures. Prior to joining St. Vincent Health in 2008, Mr. White was the Chief Financial Officer of Lilly USA, a subsidiary of Eli Lilly and Company, where he also held leadership positions in Treasury and Corporate Finance and Investment Banking in the Corporate Strategy Group. Mr. White is a director of OneAmerica Financial Insurance Partners, Inc., a mutual insurance and financial services company based in Indianapolis, Indiana and Delta Dental of Washington, a Seattle based dental insurance company. From June 2014 until August 2016, Mr. White served on the board of directors of Washington Prime Group, a NYSE REIT that invests in shopping centers. From July 2015 until March 2017, Mr. White served on the board of directors of CoLucid Pharmaceuticals, Inc., a public pharmaceutical company. Mr. White earned his B.S. from Wilberforce University in Accounting and his M.B.A. in finance from Indiana University. - Marvin L. White，目前担任董事的任期始于2020年10月。White先生曾担任Aptevo Therapeutics Inc.（“Aptevo”）的总裁兼首席执行官，并自2016年8月起担任其董事会成员。White先生于2010年6月首次担任Emergent的董事，直到2016年5月从Emergent董事会辞职。在加入Aptevo之前，他还曾担任Emergent的顾问。从2008年到2014年3月，White先生担任St. Vincent Health的首席财务官，负责所有19家医院和36家合资企业的财务、材料管理、会计、患者财务服务和管理式医疗。在2008年加入St. Vincent Health之前，White先生是Lilly USA（礼来公司的子公司）的首席财务官，他还曾在该公司的企业战略集团担任财务和企业融资以及投资银行方面的领导职务。怀特先生是OneAmerica Financial Insurance Partners，Inc.的董事，该公司是一家位于印第安纳州印第安纳波利斯的相互保险和金融服务公司，也是一家位于西雅图的牙科保险公司Delta Dental of Washington。从2014年6月到2016年8月，White先生在Washington Prime Group的董事会任职，这是一家投资于购物中心的NYSE REIT。从2015年7月到2017年3月，怀特先生在上市制药公司CoLucid Pharmaceuticals，Inc.的董事会任职。White先生获得了威尔伯福斯大学会计学学士学位和印第安纳大学金融硕士学位。
- Marvin L. White,current tenure as a director began in October 2020. Mr. White has served as President and Chief Executive Officer of Aptevo Therapeutics Inc. ("Aptevo") and as a member of its Board of Directors since August 2016. Mr. White first served as a director of Emergent in June 2010, until his resignation from the Emergent Board of Directors in May 2016. He also served as a consultant to Emergent prior to joining Aptevo. From 2008 to March 2014, Mr. White served as the Chief Financial Officer of St. Vincent Health, and was responsible for finance, materials management, accounting, patient financial services and managed care for all 19 hospitals and 36 joint ventures. Prior to joining St. Vincent Health in 2008, Mr. White was the Chief Financial Officer of Lilly USA, a subsidiary of Eli Lilly and Company, where he also held leadership positions in Treasury and Corporate Finance and Investment Banking in the Corporate Strategy Group. Mr. White is a director of OneAmerica Financial Insurance Partners, Inc., a mutual insurance and financial services company based in Indianapolis, Indiana and Delta Dental of Washington, a Seattle based dental insurance company. From June 2014 until August 2016, Mr. White served on the board of directors of Washington Prime Group, a NYSE REIT that invests in shopping centers. From July 2015 until March 2017, Mr. White served on the board of directors of CoLucid Pharmaceuticals, Inc., a public pharmaceutical company. Mr. White earned his B.S. from Wilberforce University in Accounting and his M.B.A. in finance from Indiana University.
- Arthur M. Pappas
-
Arthur M. Pappas，Pappas先生从2011年2月开始担任我司董事。Pappas先生从1994年开始担任Pappas Ventures的经营合伙人，该公司投资于生命科学、生物技术、专业药物、药物递送、医疗设备以及相关风险投资。Pappas先生在俄亥俄大学（Ohio State University）获得生物学理学学士学位，在泽维尔大学（Xavier University）获得金融学工商管理硕士学位。
Arthur M. Pappas has served as the Chairman of the Board since December 2005. Since 1994 Arthur M. Pappas has served as Managing Partner of Pappas Capital, LLC, a company that invests exclusively in the life sciences sector. From 1989 to 1994 Mr. Pappas served as the Chief Executive Officer of Glaxo Far East Pte Ltd., Glaxo Latin America, Inc. and various other subsidiaries of Glaxo Holdings, plc, a global pharmaceutical company. From 1987 to 1989 Mr. Pappas served as Vice President of Commercial Operations for Abbott Laboratories International, Ltd. From 1982 to 1987 Mr. Pappas served as Chief Executive Officer of Merrell Dow Brazil and Merrell Dow Pharmaceuticals Pacific, Ltd., which were subsidiaries of Merrell Dow Pharmaceuticals, Inc., a pharmaceutical company. Mr. Pappas currently serves as a director of Afferent Pharmaceuticals, Inc. and Aura Biosciences, Inc., as well as a director for several non-profit organizations. He also served as a director of Chimerix, Inc. (NASDAQ: CRMX), a biopharmaceutical company, from February 2011 to June 2014 and CardioDx, Inc., from May 2009 to July 2014. Mr. Pappas has previously served on numerous boards of directors, including those of Glaxo Holdings, plc, and the predecessor of Quintiles, Inc., a global provider of biopharmaceutical outsourcing services. Mr. Pappas is a decorated Vietnam veteran, having served as an officer in the U.S. Army 101st Airborne Division and 2nd PSYOP Airborne Group JFK Special Warfare Center. Mr. Pappas earned a B.S. in Biology from Ohio State University and an M.B.A. in Finance from Xavier University. - Arthur M. Pappas，Pappas先生从2011年2月开始担任我司董事。Pappas先生从1994年开始担任Pappas Ventures的经营合伙人，该公司投资于生命科学、生物技术、专业药物、药物递送、医疗设备以及相关风险投资。Pappas先生在俄亥俄大学（Ohio State University）获得生物学理学学士学位，在泽维尔大学（Xavier University）获得金融学工商管理硕士学位。
- Arthur M. Pappas has served as the Chairman of the Board since December 2005. Since 1994 Arthur M. Pappas has served as Managing Partner of Pappas Capital, LLC, a company that invests exclusively in the life sciences sector. From 1989 to 1994 Mr. Pappas served as the Chief Executive Officer of Glaxo Far East Pte Ltd., Glaxo Latin America, Inc. and various other subsidiaries of Glaxo Holdings, plc, a global pharmaceutical company. From 1987 to 1989 Mr. Pappas served as Vice President of Commercial Operations for Abbott Laboratories International, Ltd. From 1982 to 1987 Mr. Pappas served as Chief Executive Officer of Merrell Dow Brazil and Merrell Dow Pharmaceuticals Pacific, Ltd., which were subsidiaries of Merrell Dow Pharmaceuticals, Inc., a pharmaceutical company. Mr. Pappas currently serves as a director of Afferent Pharmaceuticals, Inc. and Aura Biosciences, Inc., as well as a director for several non-profit organizations. He also served as a director of Chimerix, Inc. (NASDAQ: CRMX), a biopharmaceutical company, from February 2011 to June 2014 and CardioDx, Inc., from May 2009 to July 2014. Mr. Pappas has previously served on numerous boards of directors, including those of Glaxo Holdings, plc, and the predecessor of Quintiles, Inc., a global provider of biopharmaceutical outsourcing services. Mr. Pappas is a decorated Vietnam veteran, having served as an officer in the U.S. Army 101st Airborne Division and 2nd PSYOP Airborne Group JFK Special Warfare Center. Mr. Pappas earned a B.S. in Biology from Ohio State University and an M.B.A. in Finance from Xavier University.
- Alison Lawton
-
Alison Lawton， 她是二类董事，并担任我们的董事（2012年11月以来）。直到2014年1月，她曾担任OvaScience公司（公开交易的生命科学公司）的首席营运官。从1991年到2013年，她曾担任Genzyme Corporation和Sanofi-Aventis公司的多种执行，并不断被提拔。此后，该公司于2011年收购Genzyme公司（均为全球生物制药公司）。她曾担任Genzyme Biosurgery公司的主管，在那里她负责Genzyme公司的全球骨科、外科和细胞疗法和再生医学业务。此前，她曾负责Genzyme公司的全球市场准入，其中包括法规事务、全球健康结果和战略定价、全球公共政策、全球产品安全与风险管理。加入Genzyme公司之前，她曾任职 Parke-Davis公司（一个制药公司，位于英国）7年。她任职于Cubist Pharmaceuticals公司（公开上市的生物制药公司）的董事会。
Alison Lawton is a Class II director who has served as a member of our Board of Directors since November 2012. Ms. Lawton has been the Chief Executive Officer, President and Director of Kaleido Biosciences, Inc. Kaleido since 2018. She previously served as President and Chief Operating Officer of Kaleido, beginning in December 2017. Ms. Lawton was Chief Operating Officer at Aura Biosciences, Inc. from 2015 to 2017. Ms. Lawton also served as Chief Operating Officer at OvaScience Inc., a life sciences company, from January 2013 to January 2014. In addition, from 2014 to 2017 Ms. Lawton served as a biotech consultant for various companies, including as Chief Operating Officer consultant at X4 Pharmaceuticals. Ms. Lawton worked at various positions of increasing responsibility at Genzyme Corporation (Genzyme) and subsequently at Sanofi-Aventis, following its 2011 acquisition of Genzyme, each a global biopharmaceutical company. Ms. Lawton served as head of Genzyme Biosurgery, where she was responsible for Genzyme’s global orthopedics, surgical and cell therapy and regenerative medicine businesses. Prior to that, Ms. Lawton oversaw Global Market Access at Genzyme, which included Regulatory Affairs, Global Health Outcomes and Strategic Pricing, Global Public Policy and Global Product Safety & Risk Management. Before joining Genzyme, Ms. Lawton worked for seven years in the United Kingdom at Parke-Davis, a pharmaceutical company. Ms. Lawton serves on the board of directors of ProQR Therapeutics, a public biopharmaceutical company. She also has served on the boards of directors of CoLucid Pharmaceuticals, Inc. until its acquisition by Eli Lilly & Co. and of Cubist Pharmaceuticals until its acquisition by Merck & Co., Inc. She is past President and Chair of the Board of Regulatory Affairs Professional Society and past FDA Advisory Committee member for the Cell and Gene Therapy Committee. She earned her B.Sc. in Pharmacology, with honors, from King’s College London. - Alison Lawton， 她是二类董事，并担任我们的董事（2012年11月以来）。直到2014年1月，她曾担任OvaScience公司（公开交易的生命科学公司）的首席营运官。从1991年到2013年，她曾担任Genzyme Corporation和Sanofi-Aventis公司的多种执行，并不断被提拔。此后，该公司于2011年收购Genzyme公司（均为全球生物制药公司）。她曾担任Genzyme Biosurgery公司的主管，在那里她负责Genzyme公司的全球骨科、外科和细胞疗法和再生医学业务。此前，她曾负责Genzyme公司的全球市场准入，其中包括法规事务、全球健康结果和战略定价、全球公共政策、全球产品安全与风险管理。加入Genzyme公司之前，她曾任职 Parke-Davis公司（一个制药公司，位于英国）7年。她任职于Cubist Pharmaceuticals公司（公开上市的生物制药公司）的董事会。
- Alison Lawton is a Class II director who has served as a member of our Board of Directors since November 2012. Ms. Lawton has been the Chief Executive Officer, President and Director of Kaleido Biosciences, Inc. Kaleido since 2018. She previously served as President and Chief Operating Officer of Kaleido, beginning in December 2017. Ms. Lawton was Chief Operating Officer at Aura Biosciences, Inc. from 2015 to 2017. Ms. Lawton also served as Chief Operating Officer at OvaScience Inc., a life sciences company, from January 2013 to January 2014. In addition, from 2014 to 2017 Ms. Lawton served as a biotech consultant for various companies, including as Chief Operating Officer consultant at X4 Pharmaceuticals. Ms. Lawton worked at various positions of increasing responsibility at Genzyme Corporation (Genzyme) and subsequently at Sanofi-Aventis, following its 2011 acquisition of Genzyme, each a global biopharmaceutical company. Ms. Lawton served as head of Genzyme Biosurgery, where she was responsible for Genzyme’s global orthopedics, surgical and cell therapy and regenerative medicine businesses. Prior to that, Ms. Lawton oversaw Global Market Access at Genzyme, which included Regulatory Affairs, Global Health Outcomes and Strategic Pricing, Global Public Policy and Global Product Safety & Risk Management. Before joining Genzyme, Ms. Lawton worked for seven years in the United Kingdom at Parke-Davis, a pharmaceutical company. Ms. Lawton serves on the board of directors of ProQR Therapeutics, a public biopharmaceutical company. She also has served on the boards of directors of CoLucid Pharmaceuticals, Inc. until its acquisition by Eli Lilly & Co. and of Cubist Pharmaceuticals until its acquisition by Merck & Co., Inc. She is past President and Chair of the Board of Regulatory Affairs Professional Society and past FDA Advisory Committee member for the Cell and Gene Therapy Committee. She earned her B.Sc. in Pharmacology, with honors, from King’s College London.
- Arthur M. Pappas
-
自2009年5月，Arthur M. Pappas一直担任我们的董事会成员。自1994年以来，他出任Pappas Ventures运营合伙人，该公司投资于生命科学和医疗技术。 1989年至1994年，他曾担任Glaxo Far East Pte Ltd., Glaxo Latin America, Inc 和多家Glaxo Holdings附属公司的首席执行官，这是一家全球性制药公司。从1982年至1987年，他曾担任Merrell Dow Brazil 和 Merrell Dow Pharmaceuticals Pacific, Ltd.首席执行官，这两家公司是Merrell Dow Pharmaceuticals子公司。他目前担任Chimerix公司的董事，并曾担任多家公司董事，包括 Glaxo Holdings, plc， 和Quintiles Transnational Corp.他是越战老兵，曾担任军官的第101空降师。他赢得了泽维尔大学金融MBA来自和俄亥俄州立大学生物学学士学位。
Arthur M. Pappas has served as a member of our board of directors since May 2009. Since 1994 Mr. Pappas has served as a managing partner of Pappas Ventures, a company investing in life sciences and medical technologies. From 1989 to 1994 Mr. Pappas served as Chief Executive Officer of Glaxo Far East Pte Ltd., Glaxo Latin America, Inc., and various other subsidiaries of Glaxo Holdings, plc, a global pharmaceutical company. From 1982 to 1987 Mr. Pappas served as Chief Executive Officer of Merrell Dow Brazil and Merrell Dow Pharmaceuticals Pacific, Ltd., which were subsidiaries of Merrell Dow Pharmaceuticals, Inc. Mr. Pappas currently sits on the board of directors of Chimerix, Inc., and has previously served on numerous boards of directors, including those of Glaxo Holdings, plc, and Quintiles Transnational Corp. Mr. Pappas is a decorated Vietnam veteran, having served as an officer in the 101st Airborne Division. Mr. Pappas earned an M.B.A. in Finance from Xavier University and a B.S. in Biology from Ohio State University. - 自2009年5月，Arthur M. Pappas一直担任我们的董事会成员。自1994年以来，他出任Pappas Ventures运营合伙人，该公司投资于生命科学和医疗技术。 1989年至1994年，他曾担任Glaxo Far East Pte Ltd., Glaxo Latin America, Inc 和多家Glaxo Holdings附属公司的首席执行官，这是一家全球性制药公司。从1982年至1987年，他曾担任Merrell Dow Brazil 和 Merrell Dow Pharmaceuticals Pacific, Ltd.首席执行官，这两家公司是Merrell Dow Pharmaceuticals子公司。他目前担任Chimerix公司的董事，并曾担任多家公司董事，包括 Glaxo Holdings, plc， 和Quintiles Transnational Corp.他是越战老兵，曾担任军官的第101空降师。他赢得了泽维尔大学金融MBA来自和俄亥俄州立大学生物学学士学位。
- Arthur M. Pappas has served as a member of our board of directors since May 2009. Since 1994 Mr. Pappas has served as a managing partner of Pappas Ventures, a company investing in life sciences and medical technologies. From 1989 to 1994 Mr. Pappas served as Chief Executive Officer of Glaxo Far East Pte Ltd., Glaxo Latin America, Inc., and various other subsidiaries of Glaxo Holdings, plc, a global pharmaceutical company. From 1982 to 1987 Mr. Pappas served as Chief Executive Officer of Merrell Dow Brazil and Merrell Dow Pharmaceuticals Pacific, Ltd., which were subsidiaries of Merrell Dow Pharmaceuticals, Inc. Mr. Pappas currently sits on the board of directors of Chimerix, Inc., and has previously served on numerous boards of directors, including those of Glaxo Holdings, plc, and Quintiles Transnational Corp. Mr. Pappas is a decorated Vietnam veteran, having served as an officer in the 101st Airborne Division. Mr. Pappas earned an M.B.A. in Finance from Xavier University and a B.S. in Biology from Ohio State University.
高管简历
中英对照 | 中文 | 英文- Thomas P. Mathers
Thomas P. Mathers自2011年6月以来一直担任我们的首席执行官。2015年1月以来，他一直担任我们董事会的成员。2011年6月以来，他担任Déclion Holdings LLC（生物技术公司，从事declensional peptides的开发，神经退行性疾病，传染性疾病和癌症的治疗平台）和其附属公司的主席和首席执行官。2006年6月以来，他一直任职生物技术工业组织的董事会职务。直到2014年12月，他担任CureFAKtor Pharmaceuticals, LLC（一个私营生物制药公司）的临时总经理。此前从2003年11月到2011年6月Peptimmune, Inc.根据破产法第7章（Chapter 7 bankruptcy）申请破产，他担任Peptimmune, Inc.（生物科技公司，从事肽和氨基酸共聚物的开发，来治疗中枢神经系统和慢性炎性疾病）的总裁、首席执行官和董事。此前，他曾是Cell Based Delivery, Inc.的总裁、首席执行官和董事。他曾是Cardion Pharmaceuticals, Inc. 的总经理和公司副总裁。他曾在Genzyme Corporation担任各种职务，包括战略发展副总裁、心血管全球营销高级董事以及各种营销管理职位。他曾担任 CureFAKtor Pharmaceuticals, LLC公司的董事（从2012年5月到2014年12月）。从1988年到1991年，他担任美国陆军航空（the United States Army - Aviation）的上尉。1988年他获得西点军校（West Point）美国军事学院（United States Military Academy）的工程学士学位。
Thomas P. Mathers has served as our Chief Executive Officer since June 2011. Since January 2015 Mr. Mathers has also served as a member of our Board of Directors. He also serves as the Chairman and Chief Executive Officer of Déclion Holdings LLC, a biotechnology company focused on developing declensional peptides as a platform for the treatment of neurodegenerative diseases, infectious diseases and cancer, and its affiliates and has held these roles since June 2011. Since June 2006 Mr. Mathers has served on the board of directors of the Biotechnology Industry Organization. Until December 2014 Mr. Mathers also served as the interim general manager of CureFAKtor Pharmaceuticals, LLC, a privately held biopharmaceutical company. Previously, Mr. Mathers served as the President and Chief Executive Officer and a director of Peptimmune, Inc., a biotechnology company focused on developing peptides and amino acid copolymers for the treatment of CNS and chronic inflammatory diseases, from November 2003 until June 2011 when the company filed for Chapter 7 bankruptcy. Prior to that, Mr. Mathers was the President and Chief Executive Officer and a director of Cell Based Delivery, Inc., and he was the General Manager and Corporate Vice President of Cardion Pharmaceuticals, Inc. Mr. Mathers also held a variety of positions at Genzyme Corporation, including Vice President, Strategic Development; Senior Director, Cardiovascular Global Marketing; and various marketing management positions. He also served as a director of CureFAKtor Pharmaceuticals, LLC from May 2012 to December 2014. Mr. Mathers served as a captain in the United States Army-Aviation from 1988 through 1991 and he received his bachelor’s degree in engineering from the United States Military Academy, West Point, in 1988.- Thomas P. Mathers自2011年6月以来一直担任我们的首席执行官。2015年1月以来，他一直担任我们董事会的成员。2011年6月以来，他担任Déclion Holdings LLC（生物技术公司，从事declensional peptides的开发，神经退行性疾病，传染性疾病和癌症的治疗平台）和其附属公司的主席和首席执行官。2006年6月以来，他一直任职生物技术工业组织的董事会职务。直到2014年12月，他担任CureFAKtor Pharmaceuticals, LLC（一个私营生物制药公司）的临时总经理。此前从2003年11月到2011年6月Peptimmune, Inc.根据破产法第7章（Chapter 7 bankruptcy）申请破产，他担任Peptimmune, Inc.（生物科技公司，从事肽和氨基酸共聚物的开发，来治疗中枢神经系统和慢性炎性疾病）的总裁、首席执行官和董事。此前，他曾是Cell Based Delivery, Inc.的总裁、首席执行官和董事。他曾是Cardion Pharmaceuticals, Inc. 的总经理和公司副总裁。他曾在Genzyme Corporation担任各种职务，包括战略发展副总裁、心血管全球营销高级董事以及各种营销管理职位。他曾担任 CureFAKtor Pharmaceuticals, LLC公司的董事（从2012年5月到2014年12月）。从1988年到1991年，他担任美国陆军航空（the United States Army - Aviation）的上尉。1988年他获得西点军校（West Point）美国军事学院（United States Military Academy）的工程学士学位。
- Thomas P. Mathers has served as our Chief Executive Officer since June 2011. Since January 2015 Mr. Mathers has also served as a member of our Board of Directors. He also serves as the Chairman and Chief Executive Officer of Déclion Holdings LLC, a biotechnology company focused on developing declensional peptides as a platform for the treatment of neurodegenerative diseases, infectious diseases and cancer, and its affiliates and has held these roles since June 2011. Since June 2006 Mr. Mathers has served on the board of directors of the Biotechnology Industry Organization. Until December 2014 Mr. Mathers also served as the interim general manager of CureFAKtor Pharmaceuticals, LLC, a privately held biopharmaceutical company. Previously, Mr. Mathers served as the President and Chief Executive Officer and a director of Peptimmune, Inc., a biotechnology company focused on developing peptides and amino acid copolymers for the treatment of CNS and chronic inflammatory diseases, from November 2003 until June 2011 when the company filed for Chapter 7 bankruptcy. Prior to that, Mr. Mathers was the President and Chief Executive Officer and a director of Cell Based Delivery, Inc., and he was the General Manager and Corporate Vice President of Cardion Pharmaceuticals, Inc. Mr. Mathers also held a variety of positions at Genzyme Corporation, including Vice President, Strategic Development; Senior Director, Cardiovascular Global Marketing; and various marketing management positions. He also served as a director of CureFAKtor Pharmaceuticals, LLC from May 2012 to December 2014. Mr. Mathers served as a captain in the United States Army-Aviation from 1988 through 1991 and he received his bachelor’s degree in engineering from the United States Military Academy, West Point, in 1988.
- Matthew D. Dallas
Matthew D. Dallas自2015年2月起担任公司首席财务官。之前，他曾在AVEO Pharmaceuticals, Inc.NASDAQ：AVEO（一家生物技术公司）任职：2014年7月到2015年2月担任金融副总裁、风险官和代理首席会计主管；2012年7月到2013年6月担任金融高级总监；2012年7月到2013年6月担任金融规划主管；2011年3月到2012年6月担任金融规划和分析副主管。从2000年12月到2011年3月在Genzyme Corporation（一家全球生物技术公司）担任多个职位，最近的职位是担任金融副主管。他还在NEN Life Sciences and Kimberly-Clark Corporation担任金融和会计职位。他持有the University of Tennessee金融学士学位。
Matthew D. Dallas,has served as our Chief Financial Officer since February 2015. Previously, Mr. Dallas served as the Vice President of Finance, Treasurer and Acting Principal Accounting Officer from July 2014 to February 2015 Senior Director of Finance from July 2012 to June 2013 Director of Financial Planning and Analysis from July 2012 to June 2013 and Associate Director of Financial Planning and Analysis from March 2011 to June 2012 at AVEO Pharmaceuticals, Inc., a biotechnology company. From December 2000 to March 2011 Mr. Dallas held a variety of roles at Genzyme Corporation, a global biotechnology company, most recently serving as the Associate Director of Finance. He has also held various positions in finance and accounting at NEN Life Sciences and Kimberly-Clark Corporation. Mr. Dallas received his bachelor’s degree in finance from the University of Tennessee.- Matthew D. Dallas自2015年2月起担任公司首席财务官。之前，他曾在AVEO Pharmaceuticals, Inc.NASDAQ：AVEO（一家生物技术公司）任职：2014年7月到2015年2月担任金融副总裁、风险官和代理首席会计主管；2012年7月到2013年6月担任金融高级总监；2012年7月到2013年6月担任金融规划主管；2011年3月到2012年6月担任金融规划和分析副主管。从2000年12月到2011年3月在Genzyme Corporation（一家全球生物技术公司）担任多个职位，最近的职位是担任金融副主管。他还在NEN Life Sciences and Kimberly-Clark Corporation担任金融和会计职位。他持有the University of Tennessee金融学士学位。
- Matthew D. Dallas,has served as our Chief Financial Officer since February 2015. Previously, Mr. Dallas served as the Vice President of Finance, Treasurer and Acting Principal Accounting Officer from July 2014 to February 2015 Senior Director of Finance from July 2012 to June 2013 Director of Financial Planning and Analysis from July 2012 to June 2013 and Associate Director of Financial Planning and Analysis from March 2011 to June 2012 at AVEO Pharmaceuticals, Inc., a biotechnology company. From December 2000 to March 2011 Mr. Dallas held a variety of roles at Genzyme Corporation, a global biotechnology company, most recently serving as the Associate Director of Finance. He has also held various positions in finance and accounting at NEN Life Sciences and Kimberly-Clark Corporation. Mr. Dallas received his bachelor’s degree in finance from the University of Tennessee.
- Bernice Kuca
Bernice Kuca自2011年7月起担任临床和监管运营副总裁。从2009年3月到2011年7月，她担任Peptimmune, Inc.临床运营主管，提供临床运营和战略项目领导。在此之前，她在公司担任多个临床主管职位，包括Sepracor, Inc., Idenix Pharmaceuticals, Inc., Ziopharm Oncology, Inc. （NASDAQ：ZIOP）以及Oscient Pharmaceuticals Corporation。除了职业经验之外，她现在还担任CAN DO MS（一家非盈利组织）志愿者董事会成员。Ms. Kuca持有布法罗纽约州立大学（the State University of New York）生物学学士学位；波士顿大学（Boston University）应用解剖学和生理学硕士学位；哈佛大学Extension School工商管理特殊研究毕业证书。
Bernice Kuca, has served as our Head, Clinical and Regulatory Operations since July 2011. From March 2009 through July 2011 Ms. Kuca was the Head of Clinical Operations at Peptimmune, Inc., providing clinical operations and strategic program leadership. Prior to that time, Ms. Kuca has served in a variety of clinical director roles at companies including Sepracor, Inc., Idenix Pharmaceuticals, Inc., Ziopharm Oncology, Inc., and Oscient Pharmaceuticals Corporation. In addition to her professional experience, Ms. Kuca currently serves on the volunteer board of directors of CAN DO MS, a national non-profit organization. Ms. Kuca received her bachelor’s degree in biology from the State University of New York at Buffalo, her master’s degree in applied anatomy and physiology from Boston University, and a graduate certificate of special studies in administration and management from Harvard University Extension School.- Bernice Kuca自2011年7月起担任临床和监管运营副总裁。从2009年3月到2011年7月，她担任Peptimmune, Inc.临床运营主管，提供临床运营和战略项目领导。在此之前，她在公司担任多个临床主管职位，包括Sepracor, Inc., Idenix Pharmaceuticals, Inc., Ziopharm Oncology, Inc. （NASDAQ：ZIOP）以及Oscient Pharmaceuticals Corporation。除了职业经验之外，她现在还担任CAN DO MS（一家非盈利组织）志愿者董事会成员。Ms. Kuca持有布法罗纽约州立大学（the State University of New York）生物学学士学位；波士顿大学（Boston University）应用解剖学和生理学硕士学位；哈佛大学Extension School工商管理特殊研究毕业证书。
- Bernice Kuca, has served as our Head, Clinical and Regulatory Operations since July 2011. From March 2009 through July 2011 Ms. Kuca was the Head of Clinical Operations at Peptimmune, Inc., providing clinical operations and strategic program leadership. Prior to that time, Ms. Kuca has served in a variety of clinical director roles at companies including Sepracor, Inc., Idenix Pharmaceuticals, Inc., Ziopharm Oncology, Inc., and Oscient Pharmaceuticals Corporation. In addition to her professional experience, Ms. Kuca currently serves on the volunteer board of directors of CAN DO MS, a national non-profit organization. Ms. Kuca received her bachelor’s degree in biology from the State University of New York at Buffalo, her master’s degree in applied anatomy and physiology from Boston University, and a graduate certificate of special studies in administration and management from Harvard University Extension School.
- Linda C. Hogan
Linda C. Hogan自2008年9月起担任公司业务开发副总裁。自2006年12月起她开始担任LLH Associates, LLC（一家提供业务开发和战略交易的咨询和顾问公司）总裁和创始人。加入公司之前，她曾于2005年到2014年12月自Care Capital, LLC担任常驻执行官。她还担任ClearView Projects业务开发副总裁；Aventis Pharmaceuticals副总裁、全球业务开发美国集团主管；并在其子公司担任多个其他职位。开启医药职业之前，她曾担任药学实践助理教授；堪萨斯大学药学院（the University of Kansas School of Pharmacy ）以及堪萨斯大学医疗中心（Kansas University Medical Center）药品信息服务主管。她持有Rockhurst College医院药学硕士学位以及工商管理硕士学位；以及国际许可贸易工作者协会CLP。
Linda C. Hogan, has served as our Head, Business Development and Strategy since September 2008. Since December 2006 Ms. Hogan has also served as the President and Founder of LLH Associates, LLC, a consulting and advisory firm for business development and strategy transactions. Prior to joining us, she was an Executive in Residence at Care Capital, LLC from November 2005 to December 2014. She also served as Vice President of Business Development at ClearView Projects, Vice President, U.S. Group Head, Global Business Development at Aventis Pharmaceuticals, and a variety of other roles in its predecessor companies. Prior to her pharma career, Ms. Hogan was Assistant Professor of Pharmacy Practice and Director of Drug Information Services at the University of Kansas School of Pharmacy and the Kansas University Medical Center. Ms. Hogan received a master’s degree in hospital pharmacy, a master’s in business administration from Rockhurst College and a CLP from the Licensing Executive Society.- Linda C. Hogan自2008年9月起担任公司业务开发副总裁。自2006年12月起她开始担任LLH Associates, LLC（一家提供业务开发和战略交易的咨询和顾问公司）总裁和创始人。加入公司之前，她曾于2005年到2014年12月自Care Capital, LLC担任常驻执行官。她还担任ClearView Projects业务开发副总裁；Aventis Pharmaceuticals副总裁、全球业务开发美国集团主管；并在其子公司担任多个其他职位。开启医药职业之前，她曾担任药学实践助理教授；堪萨斯大学药学院（the University of Kansas School of Pharmacy ）以及堪萨斯大学医疗中心（Kansas University Medical Center）药品信息服务主管。她持有Rockhurst College医院药学硕士学位以及工商管理硕士学位；以及国际许可贸易工作者协会CLP。
- Linda C. Hogan, has served as our Head, Business Development and Strategy since September 2008. Since December 2006 Ms. Hogan has also served as the President and Founder of LLH Associates, LLC, a consulting and advisory firm for business development and strategy transactions. Prior to joining us, she was an Executive in Residence at Care Capital, LLC from November 2005 to December 2014. She also served as Vice President of Business Development at ClearView Projects, Vice President, U.S. Group Head, Global Business Development at Aventis Pharmaceuticals, and a variety of other roles in its predecessor companies. Prior to her pharma career, Ms. Hogan was Assistant Professor of Pharmacy Practice and Director of Drug Information Services at the University of Kansas School of Pharmacy and the Kansas University Medical Center. Ms. Hogan received a master’s degree in hospital pharmacy, a master’s in business administration from Rockhurst College and a CLP from the Licensing Executive Society.
- Raymond D. Skwierczynski
Raymond D. Skwierczynski， 他获得博士学位。2015年11月以来，他担任我们制药业务负责人。此前，他担任武田制药公司（Takeda Pharmaceuticals，原千年制药公司（Millennium Pharmaceuticals））医药技术研发实验室高级主管。他曾在此带领科技人员部门，负责小分子的口服和静脉途径从发现到商业化的各个方面制定和分析发展。他对ixazomib and alseritib的后期发展做出贡献，他通过制药运营的注册在那里建立了临床前开发的开发和管理策略。Takeda之前，他担任3M Pharmaceuticals和Roche Carolina的各种职务，并不断被提拔。他是the United States Pharmacopeia的专家委员会成员。
Raymond D. Skwierczynski, PhD,has served as our Head, Pharmaceuticals Operations since November 2015. Previously, Dr. Skwierczynski served as Senior Director, Pharmaceutical Technology R&D Laboratory at Takeda Pharmaceuticals formerly Millennium Pharmaceuticals where he led departments of scientists and engineers responsible for all aspects of small-molecule formulation and analytical development from discovery to commercialization for oral and IV routes of delivery. Dr. Skwierczynski contributed to the late-stage development of ixazomib and alseritib, where he established development and regulatory strategies for pre-clinical development through registration related to pharmaceutical operations. Prior to Takeda, Dr. Skwierczynski held positions of increasing responsibility with 3M Pharmaceuticals and Roche Carolina. Dr. Skwierczynski also serves as a member of an Expert Committee for the United States Pharmacopeia.- Raymond D. Skwierczynski， 他获得博士学位。2015年11月以来，他担任我们制药业务负责人。此前，他担任武田制药公司（Takeda Pharmaceuticals，原千年制药公司（Millennium Pharmaceuticals））医药技术研发实验室高级主管。他曾在此带领科技人员部门，负责小分子的口服和静脉途径从发现到商业化的各个方面制定和分析发展。他对ixazomib and alseritib的后期发展做出贡献，他通过制药运营的注册在那里建立了临床前开发的开发和管理策略。Takeda之前，他担任3M Pharmaceuticals和Roche Carolina的各种职务，并不断被提拔。他是the United States Pharmacopeia的专家委员会成员。
- Raymond D. Skwierczynski, PhD,has served as our Head, Pharmaceuticals Operations since November 2015. Previously, Dr. Skwierczynski served as Senior Director, Pharmaceutical Technology R&D Laboratory at Takeda Pharmaceuticals formerly Millennium Pharmaceuticals where he led departments of scientists and engineers responsible for all aspects of small-molecule formulation and analytical development from discovery to commercialization for oral and IV routes of delivery. Dr. Skwierczynski contributed to the late-stage development of ixazomib and alseritib, where he established development and regulatory strategies for pre-clinical development through registration related to pharmaceutical operations. Prior to Takeda, Dr. Skwierczynski held positions of increasing responsibility with 3M Pharmaceuticals and Roche Carolina. Dr. Skwierczynski also serves as a member of an Expert Committee for the United States Pharmacopeia.